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Abstract
Background
UNAIDS official estimates of national HIV prevalence are based on trends observed in ante-
natal clinic surveillance, after adjustment for the reduced fertility of HIV positive women.
Uptake of ARTmay impact on the fertility of HIV positive women, implying a need to re-esti-
mate the adjustment factors used in these calculations. We analyse the effect of antiretroviral
therapy (ART) provision on population-level fertility in Southern and East Africa, comparing
trends in HIV infected women against the secular trends observed in uninfected women.
Methods
We used fertility data from four community-based demographic and HIV surveillance sites:
Kisesa (Tanzania), Masaka and Rakai (Uganda) and uMkhanyakude (South Africa). All
births to women aged 15–44 years old were included in the analysis, classified by mother’s
age and HIV status at time of birth, and ART availability in the community. Calendar time
period of data availability relative to ART Introduction varied across the sites, from 5 years
prior to ART roll-out, to 9 years after. Calendar time was classified according to ART avail-
ability, grouped into pre ART, ART introduction (available in at least one health facility serv-
ing study site) and ART available (available in all designated health facilities serving study
site). We used Poisson regression to calculate age adjusted fertility rate ratios over time by
HIV status, and investigated the interaction between ART period and HIV status to ascertain
whether trends over time were different for HIV positive and negative women.
Results
Age-adjusted fertility rates declined significantly over time for HIV negative women in all
four studies. However HIV positives either had no change in fertility (Masaka, Rakai) or
experienced a significant increase over the same period (Kisesa, uMkhanyakude). HIV
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positive fertility was significantly lower than negative in both the pre ART period (age
adjusted fertility rate ratio (FRR) range 0.51 95%CI 0.42–0.61 to 0.73 95%CI 0.64–0.83)
and when ART was widely available (FRR range 0.57 95%CI 0.52–0.62 to 0.83 95%CI
0.78–0.87), but the difference has narrowed. The interaction terms describing the difference
in trends between HIV positives and negatives are generally significant.
Conclusions
Differences in fertility between HIV positive and HIV negative women are narrowing over
time as ART becomes more widely available in these communities. Routine adjustment of
ANC data for estimating national HIV prevalence will need to allow for the impact of
treatment.
Background
There has been a rapid scale up in the provision of Antiretroviral therapy (ART) in Sub Saha-
ran Africa in the last decade with more than 7.5 million people receiving treatment by the end
of 2012[1] this comes hand in hand with increased access to HIV testing and therefore knowl-
edge of HIV status. A large proportion of those with HIV in sub Saharan Africa are women of
reproductive age who are routinely tested for HIV at antenatal care clinics (ANC) in order to
try to prevent mother to child transmission and those testing positive are referred to clinics for
treatment [2].
Official estimates of national HIV prevalence by UNAIDS are currently based on trends
observed in antenatal clinic surveillance[3] and far more ANC data are becoming available due
to routine reports from PMTCT programs. ANC prevalence trends are then adjusted to match
prevalence levels estimated from national population surveys [4]. Part of this adjustment
accounts for the reduced fertility of HIV positive women [5, 6], however increased access to
care and treatment services and uptake of antiretroviral therapy may impact on the fertility of
HIV positive women for biological and behavioural reasons, implying a need to re-estimate the
adjustment factors used in these calculations.
There have been no longitudinal studies in Sub-Saharan Africa that have looked at the pop-
ulation level impact of ART on fertility. A few studies have measured fertility or incidence of
pregnancy in women on ART [7–10] but these lack suitable comparators (HIV negative
women in the same community) and may not be representative of all HIV positive women. A
cross sectional comparison using Malawian Demographic and Health Survey data (DHS)
found an increased probability of giving birth for HIV positive women relative to HIV negative
women between 2004 and 2010 [11] which is attributed to the increase in access to mother to
child transmission and ART services in Malawi. We analyse the effect of antiretroviral therapy
provision on population-level fertility in four cohort studies in Southern and East Africa, com-
paring trends in HIV infected women against the secular trends observed in uninfected
women.
Methods
Sites and setting
Fertility data that span the pre-ART era and the time of introduction and widespread use of
ART are available from four community-based demographic and HIV surveillance sites: Kisesa
(managed by the National Institute of Medical Research Mwanza in Northern Tanzania),
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Masaka (MRC/UVRI Uganda Research Unit on AIDS), Rakai (Rakai Health Sciences)–both in
South-west Uganda, and uMkhanyukude (Africa Centre, in KwaZulu-Natal, South Africa).
These sites belong to the network for analysing longitudinal population based data on HIV in
Africa (ALPHA)[12, 13] and have been described in detail elsewhere [14–20].
Data, HIV and ART provision
The ALPHA network standardises site-specific data to a common format to enable joint analy-
sis. In brief, each study records demographic data including dates of birth (of mothers and
infants). The studies also collect data on HIV status and provide dates of testing and test results
for their populations. In Kisesa, Rakai, and uMkhanyakude, the HIV surveys were done sepa-
rately to the demographic surveillance rounds, and data were linked afterwards using unique
identifiers. In Masaka, HIV testing was done immediately after demographic surveillance
rounds which were used to list those eligible for HIV testing. HIV testing took place in the
home for all sites apart from Kisesa where temporary village clinics are used to which people
are transported from their homes. Prior to the availability of antiretroviral therapy, testing pro-
tocols used informed consent without disclosure, so that participants did not learn the results
of the HIV research tests, however with the advent of ART, sites began to offer full pre-test and
post-test counselling to the participants during the data collection round. Participants are still
not obliged take part in the counselling or to learn their results. In Rakai the samples taken in
the home were tested at the field laboratory and then returned by a community based counsel-
lor to those participants requesting the results.
The introduction and level of uptake of ART in the different studies varies. ART was intro-
duced in the study areas between 2004 and 2005, when selected clinics were allowed to admin-
ister drugs and people were mobilised to make them aware of the new services. Further details
of ART introduction and uptake are described elsewhere[21–24].
Study Population
The population included in this analysis is women of reproductive age (15–44) living in the
surveillance areas between the time point corresponding to five years before ART was intro-
duced, to the last date for which data were available for each site up to 2015. Table 1 shows
prevalence for each site in pre and post ART years for women aged 15–49.
All live births to women aged 15–44 years old while under observation in the study were
included in the analysis, classified by mother’s age, area of residence and HIV status at time of
the birth, and by ART availability in the community. We did not include 45–49 year olds to
create the standard fertility analysis grouping of 15–49 years as there were very few births to
HIV positive women at this age.
All sites are predominately rural, though most contain areas with local markets, health and
education facilities. Area of residence is classified differently for each site. The Masaka DSS is
divided into two areas: old villages where surveillance began in 1989; and new villages where
surveillance began in November 1999. In Kisesa sub-villages are classified according to their
distance from the small trading centre on the main road. In Rakai the peri urban group com-
prises trading towns, villages along secondary roads and fishing communities and the rural cat-
egory are communities beyond those located along secondary roads. uMkhanyakude is
predominantly rural but also includes an small town and peri-urban densely populated areas.
Measures
HIV Status was classified as negative, positive and unknown. Negative person time was defined
as the time between first testing negative and last testing negative, also included in negative
Impact of Antiretroviral Therapy on Population Level Fertility
PLOS ONE | DOI:10.1371/journal.pone.0151877 March 25, 2016 3 / 16
time was a site specific time following the last negative test, this was allocated according to the
HIV incidence rates in the sites, the cut off for post negative time was taken as the time at
which the cumulated probability of becoming infected following the last test reached 5%. This
cut-off point was five years in Kisesa, Masaka and Rakai and two years in uMkhanyakude. HIV
positive time was all the person time after the first positive test. The sero conversion interval
was calculated as the mid point between first positive and last negative test and positive and
negative time was assigned accordingly. Interval censoring was invoked if the midpoint of the
sero conversion interval was longer than the site specific post negative time–in that case only
the post negative time was assigned to negative and one year pre positive time was assigned to
positive, the remainder of the interval was designated unknown. The composition of the
unknown group over time changes due to the different ways HIV positive and HIV negative
time is allocated and is also affected by participation changes in testing [25, 26] therefore we do
not present results from this group. No pressure was put on participants to receive their HIV
status as part of research survey procedures, therefore we would not expect a link between par-
ticipation in testing and fertility.
Calendar time period of data availability relative to ART introduction varied across the sites
(Fig 1), from 5 years prior to ART roll-out, to 9 years after. Calendar time was classified accord-
ing to ART availability, grouped into pre ART, ART Introduction (introduced in at least one of
the health facilities serving the community) and ART available (available in all the health facili-
ties serving the community that were designated as ART providers according to national guide-
lines). We limit results presented for the short ART roll out period to just the age specific rates,
as this time period is relatively short and is different in each site depending on the speed and
nature of the roll out therefore tells us little about general patterns and trends.
Analysis
We used Poisson regression to calculate age adjusted fertility rate ratios over time by HIV sta-
tus, and investigated the interaction between ART period and HIV status to ascertain whether
trends over time were different for HIV positive and negative women. We adjust for age and
area of residence in this analysis to control for any changes in the composition of the study site
that may have occurred between the pre and post ART periods. The analysis was performed
separately for each site and pooled across sites where appropriate, the pooled results were
adjusted by study site.
At ages under 20 HIV infection and fertility are highly correlated as many teenagers will not
yet have had sex, and only those who have had sex are at risk of becoming pregnant or
Table 1. HIV prevalence of women aged 15–49 in Study sites.
Study Site, Round (years) ART period N Prevalence (95% CI)
Kisesa 4 (2003–2004) Pre ART 3369 5.11 (4.36–5.85)
Kisesa 6 (2010–2010) Post ART 2445 7.08 (6.06–8.09)
Manicaland 3 (2003–2005) Pre ART 8273 20.45 (19.58–21.32)
Manicaland 5 (2009–2011) Post ART 6150 17.54 (16.59–18.50)
Masaka 14 (2002–2003) Pre ART 2361 14.06 (12.66–15.46)
Masaka 16 (2004–2005) Post ART 2485 17.99 (16.48–19.50)
Rakai 9 (2002–2003) Pre ART 3708 13.65 (12.54–14.75)
Rakai 12 (2006–2008) Post ART 4507 14.98 (13.93–16.02)
uMkhanyakude 1 (2002–2005) Pre ART 6533 27.2 (26.12–28.28)
uMkhanyakude 4 (2007–2008) Post ART 3604 27.58 (26.12–29.04)
doi:10.1371/journal.pone.0151877.t001
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acquiring HIV. Therefore fertility in the 15–19 year old age group is almost always higher in
HIV positive women [6]. We therefore stratify our analysis to look at 15–19 year olds and 20–
44 year olds separately.
Ethics statements
Each of the six sites contributing data to the pooled analysis has received ethical clearance from
the appropriate local ethics review bodies, and from the corresponding Institutional Review
Boards for studies which had collaborating partnerships with Northern Universities.
uMkhanyakude. Annually re-certified ethics permission for the Africa Centre DSS and
nested individual HIV surveillance among consenting adults is obtained from the Biomedical
Research Ethics Committee at the Nelson Mandela School of Medicine, University of Kwa-
Zulu-Natal. Detailed written informed consent obtained for participation in the HIV
surveillance.
Kisesa. Ethical approval for each survey round of the Kisesa cohort study granted by the
Tanzanian Medical Research Coordinating Committee and the Ethics Committee of the Lon-
don School of Hygiene and Tropical Medicine. Prior to 2006, verbal consent was obtained
directly from all study participants (aged 15 and over), due to low literacy rates among the
study population. Consent was witnessed and documented for each study participant by a
member of the sero-survey team or senior person from the community. From 2006 onward,
consent was again obtained directly from all study participants, however a written consent
option was introduced, for those able to provide this and written parental consent for those
under 18 years was also obtained.
Masaka. The MRCDSS is approved by the Uganda Virus Research Institute (UVRI) Science
and Ethics Committee (SEC) and the Uganda National Council of Science and Technology
(UNCST). Study participants provided written consent to participate in all parts of the study.
Rakai. The Rakai Community Cohort Survey is approved by the UVRI SEC and UNCST.
Literate participants provided written consent while those unable to read or write had a witness
Fig 1. Dates of ART Periods included in the analysis.
doi:10.1371/journal.pone.0151877.g001
Impact of Antiretroviral Therapy on Population Level Fertility
PLOS ONE | DOI:10.1371/journal.pone.0151877 March 25, 2016 5 / 16
sign on their behalf. Those unable to read or write used a thumbprint to document consent and
a witness would also sign as evidence that the consent had been read to the participant who
had understood and consented to participate.
Results
Overall crude and age specific fertility rates fell or remained the same between the pre and post
ART periods for all sites (Tables 2–5). Classifying the crude fertility rates by HIV status shows
that overall fertility declined in the HIV negative but remained more or less the same or
increased slightly for the HIV positive (For the HIV positive in Rakai this is true if we exclude
15–19 year olds). Age specific rates by HIV status follow this general trend for all sites apart
from slight increases in HIV negative 25–34 year olds in Masaka, 35–39 year olds in Rakai and
15–19 year olds in uMkhanyakude. Overall fertility is higher in the rural areas for all sites.
Fertility rates in HIV positive women are consistently lower than those of HIV negative
women apart from the youngest age group of 15–19 years olds (Fig 2). For all sites apart from
uMkhanyakude fertility rates in HIV positive women aged over 20 are around half those of the
negatives in the pre ART period and 0.73 (95%CI 0.64–0.83) times the negative rates in
uMkhanyakude. In the post ART period overall the differences between positive and negative
are smaller, with rate ratios ranging from 0.57 (95%CI 0.52–0.62) in Rakai to 0.83 (95%CI
0.78–0.87) in uMkhanyakude. In both periods fertility differences between positive and nega-
tive women become greater as age increases.
For all women aged 15–44 years old, age and residence adjusted fertility rates declined sig-
nificantly over time, driven by the significant decline in fertility among HIV negative women
in all four studies (Table 6). For HIV positive women in Kisesa and Masaka there is a fertility
increase of borderline significance of 1.21(95%CI 0.99–1.49) and 1.16(95%CI 0.96–1.41)
respectively, and no change in uMkhanyakude and Rakai. The interaction term between HIV
Status and ART period was significant for all sites apart from uMkhanyakude showing that the
changes in fertility over the two ART periods are significantly different for HIV positive and
HIV negative women. Excluding 15–19 year olds (Table 7) whose fertility rates are determined
largely by patterns of sexual debut, yields an overall reduction in fertility in HIV negative
women in all sites and increases among HIV positive women in Kisesa and Masaka with rate
ratios of 1.29 (95%CI 1.04–1.59) and 1.21 (95%CI 0.99–1.47) respectively, and no change in
uMkhanyakude and Rakai. In this narrower age range the interaction terms between HIV Sta-
tus and ART period were significant for all sites apart from Rakai.
The data for 20–44 year olds were pooled for the comparison of the period when ART was
available with the pre ART period, giving overall rate ratios of 0.9 (95%CI 0.89–0.92) for HIV
negative women and 1.08 (95%CI 1.01–1.16) for HIV positive women adjusted for age, resi-
dence and study site, with a significant interaction (p<0.001) between HIV status and ART
period. Focussing on 15–19 year olds (Table 8), there has been a significant reduction in fertil-
ity for HIV negative women in all sites apart from uMkhanyakude where the relative increase
was 1.11 (95%CI 1.01–1.22). The confidence intervals for the rate ratios for the HIV positive
are very large, so no real pattern can be determined.
For the two sites with data available (Kisesa and Masaka) in the 5–10 years prior to ART
there was no evidence of any interaction between HIV status and period when comparing the
periods 0–5 years and 5–10 years prior to ART (Not shown).
Person years with unknown HIV status were lowest in Masaka at 7.2% in the pre ART
period and 8.2% in the post ART period, in Rakai they were 20.2% and 27.7%, Kisesa 28.9%
and 52.0%, uMkhanyakude 46.5% and 38.3% respectively. The HIV status unknown category
includes the unclassified post negative time intervals and time before the first HIV test.
Impact of Antiretroviral Therapy on Population Level Fertility
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Discussion
This analysis uses community based cohort studies to look at the population impact of ART on
fertility. We have shown that changes in fertility have been different in HIV positive women
compared to the HIV negative over the pre and post ART Period—representing a discontinuity
since the pre ART era. This would indicate that the introduction of ART is narrowing the gap
Table 2. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for Kisesa.
All HIV-Negative HIV-Positive
Births Person Years Rate /1000 Births Person Years Rate /1000 Births Person Years Rate /1000
Kisesa
ART Period
Pre ART 5253 26.2 200.1 4108 17.6 233.1 132 1.0 126.9
ART Introduction 3715 19.5 190.6 2763 12.6 218.4 106 0.8 132.0
ART available 5895 37.2 158.3 2924 15.4 190.3 195 1.4 144.2
Age
15–19
Pre ART 846 6.2 136.6 584 3.6 160.2 12 0.1 197.6
ART Introduction 518 4.8 108.3 308 2.9 107.3 8 0.0 232.3
ART available 792 9.5 83.6 335 3.6 93.3 4 0.0 81.5
20–24
Pre ART 1461 5.4 270.8 1117 3.4 325.8 23 0.2 144.7
ART Introduction 952 3.8 250.7 714 2.3 309.2 9 0.1 97.5
ART available 1475 7.2 205.1 637 2.7 237.1 24 0.1 193.6
25–29
Pre ART 1294 4.9 264.1 1002 3.2 311.7 44 0.3 157.6
ART Introduction 897 3.3 270.1 676 2.1 315.3 34 0.2 202.7
ART available 1402 6.3 223.9 693 2.4 285.1 40 0.2 185.5
30–34
Pre ART 877 4.0 221.3 705 2.8 254.3 38 0.3 143.7
ART Introduction 746 3.1 237.7 563 2.1 272.0 32 0.2 133.3
ART available 1131 5.6 200.5 621 2.4 254.7 66 0.3 197.1
35–39
Pre ART 569 3.3 173.6 510 2.6 198.8 13 0.2 80.4
ART Introduction 426 2.4 180.9 356 1.7 212.8 16 0.2 102.2
ART available 805 5.0 162.5 454 2.3 201.2 55 0.4 131.9
40–44
Pre ART 206 2.5 81.8 190 2.0 95.0 2 0.1 17.3
ART Introduction 176 2.1 83.9 146 1.6 92.3 7 0.1 62.6
ART available 290 3.7 78.1 184 2.0 93.7 6 0.2 28.3
Residence
Rural
Pre ART 3125 13.4 233.2 2564 10.1 254.2 71 0.4 171.0
ART Introduction 2295 9.9 232.0 1805 7.2 252.4 54 0.3 162.7
ART available 3453 17.9 193.0 1932 8.9 215.9 103 0.6 164.3
Peri Urban/Urban
Pre ART 2128 12.8 165.7 1544 7.5 204.8 61 0.6 97.6
ART Introduction 1420 9.6 147.9 958 5.5 174.2 52 0.5 110.4
ART available 2442 19.3 126.3 992 6.4 154.6 92 0.7 126.8
doi:10.1371/journal.pone.0151877.t002
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in fertility rates between the HIV positive and negative. These results are similar to those found
in the cross sectional study using the Malawi DHS [11] which showed a decrease over two sur-
veys in the relative difference in fertility comparing the HIV positive and HIV negative at the
time of the survey. Since our longitudinal data can accurately measure HIV status at the time
of birth these results are a strong affirmation of the cross-sectional findings.
Table 3. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for Masaka.
All HIV-Negative HIV-Positive
Births Person Years Rate /1000 Births Person Years Rate /1000 Births Person Years Rate /1000
Masaka
ART Period
Pre ART 2524 14.8 170.1 2285 12.8 179.2 117 1.0 115.2
ART Introduction 510 3.3 153.6 466 2.8 164.0 21 0.3 83.8
ART available 4185 28.0 149.7 3672 23.3 157.4 281 2.3 119.7
Age
15–19
Pre ART 490 4.6 107.0 448 4.2 106.9 14 0.1 205.3
ART Introduction 101 1.0 105.3 91 0.9 102.3 2 0.0 112.2
ART available 665 8.5 78.5 593 7.6 77.6 25 0.2 159.4
20–24
Pre ART 766 2.9 261.3 701 2.5 277.6 32 0.2 185.3
ART Introduction 155 0.6 245.1 145 0.5 266.8 3 0.0 77.3
ART available 1115 4.9 226.6 1005 4.1 242.6 58 0.3 186.8
25–29
Pre ART 562 2.4 231.9 497 2.0 252.0 38 0.3 136.5
ART Introduction 126 0.5 229.9 115 0.4 260.9 6 0.1 101.3
ART available 1012 4.3 237.1 884 3.5 256.1 71 0.4 163.7
30–34
Pre ART 357 1.9 192.4 316 1.5 211.9 20 0.2 88.8
ART Introduction 69 0.4 154.4 63 0.4 175.6 4 0.1 69.3
ART available 786 4.0 195.3 680 3.2 215.4 71 0.5 133.5
35–39
Pre ART 263 1.7 152.8 241 1.4 168.4 11 0.2 62.7
ART Introduction 38 0.4 98.4 32 0.3 100.4 5 0.0 117.7
ART available 466 3.3 139.6 387 2.6 149.6 47 0.5 92.1
40–44
Pre ART 86 1.3 64.9 82 1.1 71.7 2 0.1 20.9
ART Introduction 21 0.3 60.4 20 0.3 68.9 1 0.0 29.0
ART available 141 2.9 48.1 123 2.3 52.6 9 0.4 22.2
Residence
Original Study Villages
Pre ART 1989 11.3 175.5 1820 9.9 183.6 81 0.7 116.5
ART Introduction 382 2.4 158.1 347 2.1 164.8 16 0.2 97.8
ART available 3003 19.5 153.7 2675 16.6 161.4 182 1.5 121.4
New villages
Pre ART 535 3.5 152.7 465 2.8 163.8 36 0.3 112.4
ART Introduction 128 0.9 141.6 119 0.7 161.6 5 0.1 57.4
ART available 1182 8.4 140.5 997 6.8 147.6 99 0.8 116.7
doi:10.1371/journal.pone.0151877.t003
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Fertility dynamics, HIV and changes due to ART are complex and can be both biological
and behavioural. Earlier studies showed that HIV positive women with further disease progres-
sion have lower fertility than the uninfected and those more recently infected [9, 10, 27].
Women with HIV also have increased risk of spontaneous abortion and still birth [28] which
lower their fertility. It is possible that the improved health of women on ART increases their
Table 4. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for Rakai.
All HIV-Negative HIV-Positive
Births Person Years Rate /1000 Births Person Years Rate /1000 Births Person Years Rate /1000
Rakai
ART Period
Pre ART 6598 51.8 127.3 5805 35.9 161.8 495 5.5 90.2
ART Introduction 2598 23.1 112.5 2304 15.5 148.5 201 2.3 88.6
ART available 6634 68.7 96.6 5736 42.8 134.0 547 6.9 79.3
Age
15–19
Pre ART 1220 13.4 91.3 1119 8.1 137.3 38 0.3 131.0
ART Introduction 310 5.7 54.8 273 3.0 90.7 7 0.1 83.9
ART available 674 17.4 38.8 601 9.2 65.2 17 0.2 90.8
20–24
Pre ART 2320 12.8 181.4 2090 9.6 217.9 137 1.1 127.4
ART Introduction 872 5.4 161.6 799 3.8 208.7 50 0.4 129.5
ART available 1953 14.8 131.8 1651 9.0 183.0 125 0.9 139.0
25–29
Pre ART 1713 10.3 166.7 1460 7.3 199.5 183 1.6 116.7
ART Introduction 791 4.8 165.2 693 3.5 199.0 80 0.6 133.4
ART available 1992 13.7 145.9 1641 8.6 190.0 178 1.6 112.6
30–34
Pre ART 830 6.4 128.8 684 4.4 156.5 96 1.3 74.6
ART Introduction 425 3.4 124.9 369 2.4 155.8 40 0.6 65.0
ART available 1309 10.9 119.7 1077 6.8 158.5 131 1.7 75.4
35–39
Pre ART 382 4.8 79.0 331 3.4 96.4 36 0.8 45.4
ART Introduction 155 2.0 76.0 130 1.5 88.9 19 0.3 55.1
ART available 572 7.1 80.3 458 4.3 106.1 65 1.3 50.8
40–44
Pre ART 133 4.1 32.4 121 3.0 40.2 5 0.5 10.5
ART Introduction 45 1.8 24.9 40 1.4 29.3 5 0.2 21.0
ART available 134 4.8 28.1 116 2.9 40.3 7 0.8 8.4
Residence
Rural
Pre ART 5483 41.2 133.2 4872 29.3 166.4 390 4.2 91.9
ART Introduction 2200 18.2 121.1 1979 12.6 157.3 157 1.7 91.7
ART available 5156 49.7 103.7 4459 31.7 140.8 400 4.7 85.9
Peri Urban/Urban
Pre ART 1115 10.7 104.5 933 6.6 141.4 105 1.2 84.3
ART Introduction 398 4.9 80.7 325 2.9 110.7 44 0.6 79.1
ART available 1401 18.5 75.7 1019 8.9 114.7 118 1.8 65.1
doi:10.1371/journal.pone.0151877.t004
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fecundity although one study found an increase in still births for HIV positive women on ART
compared to those not on ART[29].
Relationship dynamics may also change: studies from the pre ART era have shown an
increased risk of widowhood and marital dissolution for HIV positive women and low rates of
remarriage [30, 31], therefore decreasing their chances to bear more children. In the era of
Table 5. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for uMkhanyakude.
All HIV-Negative HIV-Positive
Births Person Years Rate /1000 Births Person Years Rate /1000 Births Person Years Rate /1000
uMkhanyakude
ART Period
Pre ART 3337 31.8 104.8 1550 14.0 110.7 297 3.0 98.3
ART Introduction 3899 33.7 115.7 1887 15.3 123.6 581 4.9 119.1
ART available 11601 119.5 97.0 4741 41.0 115.7 2264 23.7 95.4
Age
15–19
Pre ART 794 9.3 85.2 485 5.9 82.6 45 0.4 120.7
ART Introduction 1019 9.8 104.2 664 6.4 103.4 85 0.4 196.8
ART available 2836 32.8 86.4 1639 17.3 94.5 217 1.4 159.3
20–24
Pre ART 1014 6.6 154.5 435 2.4 182.2 95 0.7 138.7
ART Introduction 1262 7.4 169.6 589 3.2 182.4 211 1.1 184.9
ART available 3749 25.2 149.0 1631 9.3 175.4 587 4.2 140.2
25–29
Pre ART 653 4.8 135.3 209 1.3 167.0 77 0.7 116.3
ART Introduction 689 4.9 139.5 228 1.3 170.4 133 1.0 129.4
ART available 2398 20.3 118.2 661 4.5 145.5 680 5.6 122.0
30–34
Pre ART 491 4.1 121.0 206 1.2 168.9 47 0.5 86.7
ART Introduction 505 4.2 119.5 184 1.2 158.3 95 0.9 103.1
ART available 1487 15.9 93.8 397 3.0 132.4 483 5.1 94.7
35–39
Pre ART 284 3.6 79.9 154 1.5 104.6 27 0.4 64.8
ART Introduction 301 3.7 80.6 148 1.4 106.0 43 0.8 57.0
ART available 880 13.5 65.2 305 3.1 99.0 240 4.2 56.8
40–44
Pre ART 101 3.5 28.7 61 1.8 34.0 6 0.3 17.4
ART Introduction 123 3.6 34.3 74 1.7 42.9 14 0.6 23.3
ART available 251 11.9 21.1 108 3.7 29.2 57 3.3 17.3
Residence
Rural
Pre ART 2069 18.9 109.8 1076 9.6 112.2 165 1.6 100.3
ART Introduction 2382 19.8 120.2 1288 10.3 124.9 335 2.7 123.9
ART available 6955 66.2 105.1 3220 26.8 120.4 1190 12.2 97.7
Peri Urban/Urban
Pre ART 1192 12.2 97.5 452 4.2 107.1 126 1.3 95.0
ART Introduction 1387 12.6 110.0 548 4.6 118.9 234 2.0 114.8
ART available 4476 48.4 92.5 1486 13.7 108.3 1048 10.8 97.1
doi:10.1371/journal.pone.0151877.t005
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ART the risk of widowhood will decrease and marital dissolution rates may change leading to
more opportunity for childbearing.
Fertility intentions are likely also to change, HIV positive women are more likely to report
desiring fewer births than those uninfected[32] but some studies that compared fertility inten-
tions of HIV positive women on treatment to those not on treatment found an increase in
desire for children with increasing duration on ART [7, 8, 33]. It is unclear whether these inten-
tions translate into actual increases in fertility. A cross sectional study from a perinatal HIV
Research Unit in Soweto found no difference in fertility intentions between those on ART or
not[34]–however all participants were attending the HIV clinic so according to the authors, the
intentions of those not yet on treatment may have been shaped by the knowledge that ART
was available when needed. A multicounty HIV care and treatment program cohort study in
sub-Saharan Africa reported HIV positive women on treatment having 1.74(95%CI 1.19–2.54)
higher incidence of pregnancy than those not on treatment[9]. The study was unable to deter-
mine the factors underlying the results with both biological and behavioural factors being
possible.
Fig 2. Unadjusted fertility rate ratios by age and ART period comparing positives to negatives.
doi:10.1371/journal.pone.0151877.g002
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This analysis shows the extent of changes in fertility trends at the population level which is
important for modellers and policy makers. It does not tell us how much of the change is attrib-
utable to biological factors directly associated with improved health of those receiving ART,
psychological changes that alter fertility intentions, or social changes in marital dynamics and
stigma. It is important to note that in the pre ART era most people in these studies would not
have known their HIV status so reasons for low fertility in the HIV positives would not include
a conscious desire for fewer children motivated by knowledge of status. These topics need fur-
ther analysis with individual linkage to clinic data to classify time on treatment, to investigate
biological factors, and more detailed demographic and behavioural background characteristics.
Differences in fertility between HIV positive and HIV negative women are narrowing over
time as ART becomes more widely available in these communities. Routine adjustment of
Table 6. Fertility Rate Ratio (FRR) for 15–44 year olds comparing ART period with pre ART adjusted for by age and residence.
ART Period HIV Negative HIV Positive Interaction p-value*
FRR (95% CI) FRR (95% CI)
Kisesa
Pre-ART 1 1
ART Available 0.84 (0.81–0.88) 1.21 (0.99–1.49) 0.001
Masaka
Pre-ART 1 1
ART Available 0.90 (0.86–0.94) 1.16 (0.96–1.41) 0.010
uMkhanyakude
Pre-ART 1 1
ART Available 0.98 (0.93–1.03) 1.04 (0.92–1.16) 0.363
Rakai
Pre-ART 1 1
ART Available 0.84 (0.81–0.86) 0.96 (0.86–1.08) 0.020
*Interaction between ART period and HIV status
doi:10.1371/journal.pone.0151877.t006
Table 7. Fertility Rate Ratio (FRR) for 20–44 year olds comparing ART period with pre ART adjusted for by age and residence.
ART Period HIV Negative HIV Positive Interaction p-value*
FRR (95% CI) FRR (95% CI)
Kisesa
Pre-ART 1 1
ART Available 0.89 (0.86–0.93) 1.29 (1.04–1.59) 0.001
Masaka
Pre-ART 1 1.00
ART Available 0.94 (0.90–0.99) 1.21 (0.99–1.47) 0.016
uMkhanyakude
Pre-ART 1 1
ART Available 0.90 (0.84–0.95) 1.04 (0.92–1.17) 0.033
Rakai
Pre-ART 1 1
ART Available 0.93 (0.90–0.96) 1.00 (0.89–1.12) 0.252
*Interaction between ART period and HIV status
doi:10.1371/journal.pone.0151877.t007
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ANC data for estimating national HIV prevalence will need to allow for the impact of treat-
ment. Given the profound differences between fertility rate ratios and trends in infected and
uninfected women under 20 with those aged 20 and over, it would be useful to classify ANC
data on HIV prevalence by age, reporting separately on those under 20.
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